关于“少女针”的报告
-
艾媒咨询|2021年中国轻医美行业研究及产业链分析报告
本报告研究涉及企业/品牌/案例：爱美客，华熙生物，奇致激光，华韩整形，新氧，兰州生物
数据显示，2020年中国轻医美用户市场规模达到1520万人，预计到2021年将增至1813万人。在消费意识觉醒和消费需求驱动下，机构、医生在供给端强势助推轻医美行业更快速发展，预计2021年中国轻医美市场将达到798亿元，同比增长46.4%。在行业快速增长的同时，轻医美产业链各环节企业由于集中度不同导致利润分配不均，具体来看，上游原料耗材企业由于高技术壁垒，市场集中度较高，毛利率高于中下游企业，如知名玻尿酸、肉毒素产品制造企业爱美客、华熙生物等，而中下游由于竞争分散，单体获利参差不齐，更容易产生乱象。但总体来说，在行业监管加强、机构自律、平台监督等多方力量共同作用下，轻医美行业将会向线上化、品牌化、规范化发展。
According to the data, the market size of China's light medical beauty users will reach 15.2 million in 2020, and it is expected to increase to 18.13 million by 2021. Driven by the awakening of consumer awareness and consumer demand, institutions and doctors strongly boost the rapid development of light medical beauty industry in the supply side. It is estimated that China's light medical beauty market will reach 79.8 billion yuan in 2021, with a year-on-year growth of 46.4%. With the rapid growth of the industry, the profit distribution of enterprises in each link of the light medical beauty industry chain is uneven due to different concentration. Specifically, due to high technical barriers, the upstream raw materials and consumables enterprises have higher market concentration and higher gross profit rate than the middle and downstream enterprises, such as the well-known hyaluronic acid, botulinum toxin product manufacturing enterprises aimekke, Huaxi biology, etc., while the middle and downstream enterprises have higher gross profit rate due to scattered competition, Individual profit is uneven, more likely to produce chaos. But on the whole, under the joint action of industry supervision, institutional self-discipline, platform supervision and other forces, the light medical beauty industry will develop to online, brand and standardization. -
